Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer.: Final results of a multicenter phase II trial.

被引：0
作者：
Woell, E.
Kuehr, T.
Eisterer, W.
Gattringer, K.
Greil, R.
Zabernigg, A.
Hilbe, W.
Thaler, J.
机构：
[1] St Vincent Hosp Zams, Zams, Austria
[2] Klinikum Kreuzschwestern, Wels, Austria
[3] Med Univ Innsbruck, Innsbruck, Austria
[4] Kufstein Hosp, Kufstein, Austria
[5] Med Univ Klin, Salzburg, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4070
引用
收藏
页码：195S / 195S
页数：1
相关论文
共 50 条
[41]   Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma:: Final results of a GERCOR multicenter phase II study [J].
Louvet, C ;
André, T ;
Lledo, G ;
Hammel, P ;
Bleiberg, H ;
Bouleuc, C ;
Gamelin, E ;
Flesch, M ;
Cvitkovic, E ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1512-1518
[42]   Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy [J].
Ulrich-Pur, H ;
Kornek, GV ;
Fiebiger, W ;
Gedlicka, C ;
Raderer, M ;
Lenauer, A ;
Depisch, D ;
Lang, F ;
Pidlich, J ;
Scheithauer, W .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1269-1272
[43]   Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery: Final results of a phase II trial [J].
Fan, Biao ;
Su, Hao ;
Wang, Lingqian ;
Ji, Xin ;
Zhang, Yinan ;
Jia, Ziyu ;
Zhang, Ji ;
Bu, Zhaode ;
Wu, Xiaojiang .
CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
[44]   Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. [J].
Karasic, Thomas Benjamin ;
O'Hara, Mark H. ;
Teitelbaum, Ursina R. ;
Damjanov, Nevena ;
Giantonio, Bruce J. ;
d'Entremont, Tracy S. ;
Gallagher, Maryann ;
Zhang, Paul J. ;
O'Dwyer, Peter J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[45]   Results of a phase II multicenter study of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer [J].
Terashima, M. ;
Saze, Z. ;
Hosotani, R. ;
Takahashi, M. ;
Takagane, A. ;
Hachiya, O. ;
Koeda, K. ;
Matsui, S. ;
Ohashi, W. ;
Gotoh, M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46]   Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer [J].
Scheithauer, W ;
Kornek, GV ;
Raderer, M ;
Ulrich-Pur, H ;
Fiebiger, W ;
Gedlicka, C ;
Schüll, B ;
Brugger, S ;
Schneeweiss, B ;
Lang, F ;
Lenauer, A ;
Depisch, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :165-172
[47]   Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. [J].
Lee, Min-Young ;
Kim, Seung Tae ;
Lee, Jeeyun ;
Park, Se Hoon ;
Park, Young Suk ;
Lim, Ho Yeong ;
Kang, Won Ki ;
Park, Joon Oh .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48]   Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer:: final results of a multicenter phase II study [J].
Monnet, I ;
de Cremoux, H ;
Soulié, P ;
Saltiel-Voisin, S ;
Bekradda, M ;
Saltiel, JC ;
Brain, E ;
Rixe, O ;
Yataghene, Y ;
Misset, JL ;
Cvitkovic, E .
ANNALS OF ONCOLOGY, 2002, 13 (01) :103-107
[49]   Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentose Tumortherapie [J].
Woell, Ewald ;
Thaler, Josef ;
Keil, Felix ;
Eisterer, Wolfgang ;
Fridrik, Michael A. ;
Gruenberger, Birgit ;
Hejna, Michael ;
Romeder, Franz ;
Greil, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[50]   Oxaliplatin, irinotecan, and bevacizumab followed by docetaxel and bevacizumab in inoperable gastric cancer: First results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT) [J].
Woell, E. ;
Keil, F. ;
Thaler, J. ;
Gruenberger, B. ;
Hejna, M. ;
Eisterer, W. ;
Fridrik, M. A. ;
Romeder, F. ;
Greil, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345